An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression

The efficacy of anti-IL-17 therapy for various IL-17-related diseases is unexpectedly limited for unknown reasons. Luo et  al. reveal an IL-17-established mechanism consisting of Act1-SHP2 complex that primes autonomous activation of IL-17R signaling in a ligand-independent manner, sustains inflammation, thereby invalidating the efficacy of anti-IL-17 therapy.

Source: Immunity - July 19, 2023 Category: Allergy & Immunology Authors: Qiong Luo, Yijun Liu, Ke Shi, Xuecheng Shen, Yaqi Yang, Xuejiao Liang, Liangliang Lu, Wenxuan Qiao, Airu Chen, Dongmei Hong, Yang Sun, Qiang Xu Tags: Article Source Type: research